A meta-analysis of Shenqi Fuzheng combined with radiation in the treatment of nonsmall cell lung cancer.
The objective of this study is to evaluate the efficacy and toxicity reduction of Shenqi Fuzheng injection in the treatment of nonsmall cell lung cancer (NSCLC). Through searching the PubMed, WANFANG and CNKI, we recruited clinical trials related to Shenqi Fuzheng combined with radiation in the treatment of NSCLC. We extracted the treatment effective data and radiation related toxicities data. The clinical efficacy and radiation toxicity was pooled by meta-analysis. The statistical heterogeneity was evaluated by I 2 tests. By searching the related databases, we finally included 7 studies in this meta-analysis. The pooled results indicated that Shenqi Fuzheng injection can improve the clinical efficacy (relative risk [RR] =1.27, 95% confidence interval [CI]: 1.13-1.43), and decrease the radiation pneumonia (RR = 0.41, 95% CI: 0.26-0.46), radiation esophagitis (RR = 0.46, 95% CI: 0.37-0.59) and bone marrow suppression (RR = 0.44, 95% CI: 0.36-0.53). Shenqi Fuzheng injection can improve the clinical efficacy and decrease the radiation toxicities in the NSCLC patients treated with radiation.